Asprosin in Breast Cancer

Marina Hanna Thabet Ghobrial

Status: Not yet enrolling

Conditions: Breast Cancer

Treatments: Device: ELISA

Study type: Observational

Funder types: Other

Identifiers

NCT06592560

Asprosin

Details and patient eligibility

About

To evaluate the clinical utility of Asprosin measurement in breast cancer patients in comparison with healthy controls and patients with benign breast lesions.

To compare between Asprosin and the routine markers (CEA, CA15-3) as biomarkers for breast cancer diagnosis

Enrollment: 84 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Females aged (40 ± 20 years) who did not receive any chemotherapy or surgical treatment and they will be divided as follow:

Group 1: healthy controls from healthy volunteers. Group 2: patients with benign breast lesions. Group 3: breast cancer patients.

Exclusion criteria

• 1- Female patients with any other type of malignant or benign tumors. 2- Past history of chemotherapy or surgical treatment of cancer.

Trial design

84 participants in 3 patient groups

Healthy people

Treatment:

Device: ELISA

Patients with benign breast lesions

Treatment:

Device: ELISA

Patients with breast cancer

Treatment:

Device: ELISA